OmniAb, Inc. (OABI) vs Starling Oncology, Inc. (STLN)
A side-by-side comparison of OmniAb, Inc. and Starling Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
OABI
OmniAb, Inc.
$4.35HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
STLN
Starling Oncology, Inc.
$6.58HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — OABI vs STLN
growth of $100 · dividends reinvested · last 1yOABI +112.1% (+112.1%/yr)STLN +8.6% (+8.6%/yr)OABI compounded faster over this window
OABI STLN
OABI vs STLN: by the numbers
- •STLN is the larger company ($658M vs $631M market cap).
- •Both run net losses; STLN's is the smaller (-6.18% vs -115.18% net margin).
Metrics side by side
Valuation
| Metric | OABI | STLN |
|---|---|---|
| P/S ratio | 16.41 | 1.12 |
| P/B ratio | 2.42 | N/A |
Profitability
| Metric | OABI | STLN |
|---|---|---|
| Gross margin | -18.17% | 15.69% |
| Operating margin | -383.15% | -4.44% |
| Net margin | -115.18% | -6.18% |
| ROE | -17.01% | N/A |
| ROIC | -17.48% | -31.32% |
Growth (annualized)
| Metric | OABI | STLN |
|---|---|---|
| Revenue CAGR (5Y) | -4.31% | N/A |
| Total return CAGR (5Y) | -13.17% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.